Severe and refractory solar urticaria treated with intravenous immunoglobulins: A phase II multicenter study - 16/10/14
on behalf of the
Société Française de Photodermatologie
Abstract |
Background |
Retrospective data have suggested the effectiveness of intravenous immunoglobulins (IVIG) for solar urticaria (SU).
Objective |
We sought to prospectively assess the efficacy of IVIG for SU.
Methods |
We conducted a multicentric phase II study to test the efficacy of a single course of IVIG (2 g/kg) in patients with severe and refractory SU. The primary outcome was remission of SU on phototesting at 12 weeks after IVIG treatment. Secondary objectives included clinical remission, improved quality of life, and 50% improvement in disease intensity as measured on a visual analog scale.
Results |
Of the 9 patients who received IVIG injection, 2 showed remission of SU on phototesting, corresponding to a response rate of 22.2% (95% confidence interval 2.8%-60.0%). In all, 6 patients (67%) showed at least 1 response criterion after 4 weeks and 5 (56%) after 12 weeks. Response was maintained after 24 weeks for 2 patients and after 48 weeks for 1 patient. About half of the patients (56%) had moderate to severe headache.
Limitations |
Lack of control arm and small number of patients are limitations.
Conclusion |
A single course of IVIG appears insufficient to obtain prolonged significant control of SU; future evaluation of different schedules of IVIG administration is warranted.
Le texte complet de cet article est disponible en PDF.Key words : adverse events, aseptic meningitis, headache, intravenous immunoglobulins, minimal urticarial dose, phototesting, side effects, solar urticaria
Abbreviations used : DLQI, IVIG, MUD, SU, UV
Plan
| Supported by a grant from the French Ministry of Health (Programme Hospitalier de Recherche Clinique [PHRC] no. 12-06, 2010) and the Société Française de Dermatologie. Intravenous immunoglobulins were provided free of charge by LFB Biomedicaments. The funders had no role in the study design or performance, manuscript writing, or decision to publish. |
|
| Conflicts of interest: None declared. |
Vol 71 - N° 5
P. 948 - novembre 2014 Retour au numéro
Article précédent
- Retrospective review of Stevens-Johnson syndrome/toxic epidermal necrolysis treatment comparing intravenous immunoglobulin with cyclosporine
- Mark G. Kirchhof, Monica A. Miliszewski, Sheena Sikora, Anthony Papp, Jan P. Dutz
- An investigator-initiated, double-blind, vehicle-controlled pilot study: Assessment for tachyphylaxis to topically occluded halobetasol 0.05% ointment in the treatment of psoriasis
- Tali Czarnowicki, Rita V. Linkner, Mayte Suárez-Fariñas, Arie Ingber, Mark Lebwohl
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?